15000 Participants Needed

Therapies for Atopic Dermatitis

(TARGET-DERM Trial)

Recruiting at 30 trial locations
LM
LD
SH
AM
LL
Overseen ByLynda Lee Burch
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Target PharmaSolutions, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to evaluate the safety and effectiveness of current and future treatments for Atopic Dermatitis and other immune-related skin conditions. The goal is to create a research database that mirrors real-world medical practices, ultimately enhancing care for these conditions. Individuals prescribed any skin treatment for these conditions and who plan to continue visiting their doctor are suitable candidates for this trial. As a Phase 3 trial, it represents the final step before FDA approval, providing participants an opportunity to contribute to the development of potentially groundbreaking treatments.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on observing patients undergoing therapy for Immune-Mediated Inflammatory Syndrome in Children (IMISC), a condition with limited treatment options. Unlike current treatments that primarily involve supportive care and immunomodulatory therapies like IVIG or corticosteroids, this study aims to provide a comprehensive understanding of how existing therapies impact patients over time. By studying the long-term effects and outcomes of these therapies, researchers hope to identify more effective treatment protocols, optimize current therapies, and potentially uncover new therapeutic targets, ultimately improving patient care.

Who Is on the Research Team?

LD

Laura Dalfonso

Principal Investigator

Target RWE

Are You a Good Fit for This Trial?

Inclusion Criteria

1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
2. Participant has plans for future visits at the site for continued management of IMISC.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Participants are observed for safety and effectiveness of therapies for IMISC in usual clinical practice

25 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years (EU) or indefinite (US and Canada)

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Target PharmaSolutions, Inc.

Lead Sponsor

Trials
17
Recruited
5,667,000+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security